Hematopoietic Stem Cell-Targeted Neonatal Gene Therapy with a Clinically Applicable Lentiviral Vector Corrects Osteopetrosis in oc/oc Mice
- PMID: 31179768
- DOI: 10.1089/hum.2019.047
Hematopoietic Stem Cell-Targeted Neonatal Gene Therapy with a Clinically Applicable Lentiviral Vector Corrects Osteopetrosis in oc/oc Mice
Abstract
Infantile malignant osteopetrosis (IMO) is an autosomal recessive disorder characterized by nonfunctional osteoclasts. Approximately 50% of the patients have mutations in the TCIRG1 gene, encoding for a subunit of the osteoclast proton pump. Gene therapy represents a potential alternative treatment to allogeneic stem cell transplantation for IMO. The oc/oc mouse is a model of IMO characterized by a 1,500 bp deletion in the TCIRG1 gene, severe osteopetrosis, and a life span of only 3 weeks. Here we show that the osteopetrotic phenotype in oc/oc mice can be reversed by hematopoietic stem cell-targeted gene therapy with a clinically applicable lentiviral vector expressing a wild-type form of human TCIRG1 under the mammalian promoter elongation factor 1α short (EFS-hT). oc/oc c-kit+ fetal liver cells transduced with EFS-hT were transplanted into sublethally irradiated oc/oc mice by temporal vein injection 1 day after birth. A total of 9 of 12 mice survived long term (19-25 weeks) with evidence of tooth eruption, uncharacteristic of oc/oc mice. Splenocytes were harvested 19-25 weeks after transplantation and differentiated into osteoclasts on bone slices to assess resorption and on plastic to assess TCIRG1 protein expression. Vector-corrected osteoclasts showed human TCIRG1 expression by Western blot. CTX-I release relative to that mediated by oc/oc-derived osteoclasts increased 8-239-fold. Resorption pits on bone slices were observed for osteoclasts derived from 7/9 surviving transplanted oc/oc mice. Histopathology of the bones of surviving animals showed varying degrees of rescued phenotype, the majority with almost full correction. The average vector copy number per cell in the bone marrow was 1.8 ± 0.5. Overall, 75% of transplanted mice exhibited long-term survival and marked reversal of the osteopetrotic bone phenotype. These findings represent a significant step toward the clinical application of gene therapy for IMO.
Keywords: TCIRG1; gene transfer to hematopoietic stem cells; lentiviral vectors; oc/oc; osteopetrosis.
Similar articles
-
Targeting NSG Mice Engrafting Cells with a Clinically Applicable Lentiviral Vector Corrects Osteoclasts in Infantile Malignant Osteopetrosis.Hum Gene Ther. 2018 Aug;29(8):938-949. doi: 10.1089/hum.2017.053. Epub 2017 Oct 3. Hum Gene Ther. 2018. PMID: 28726516
-
Lentiviral gene transfer of TCIRG1 into peripheral blood CD34(+) cells restores osteoclast function in infantile malignant osteopetrosis.Bone. 2013 Nov;57(1):1-9. doi: 10.1016/j.bone.2013.07.026. Epub 2013 Jul 29. Bone. 2013. PMID: 23907031
-
Hematopoietic stem cell-targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc/oc mice.Blood. 2007 Jun 15;109(12):5178-85. doi: 10.1182/blood-2006-12-061382. Epub 2007 Mar 1. Blood. 2007. PMID: 17332244
-
Prospects for gene therapy of osteopetrosis.Curr Gene Ther. 2009 Jun;9(3):150-9. doi: 10.2174/156652309788488613. Curr Gene Ther. 2009. PMID: 19519360 Review.
-
Recent developments in the understanding of the pathophysiology of osteopetrosis.Eur J Endocrinol. 1996 Feb;134(2):143-56. doi: 10.1530/eje.0.1340143. Eur J Endocrinol. 1996. PMID: 8630510 Review.
Cited by
-
Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Curr Med Chem. 2024;31(13):1646-1690. doi: 10.2174/0929867330666230503144619. Curr Med Chem. 2024. PMID: 37138422 Review.
-
Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal.Mol Ther Methods Clin Dev. 2020 Dec 25;20:389-397. doi: 10.1016/j.omtm.2020.12.009. eCollection 2021 Mar 12. Mol Ther Methods Clin Dev. 2020. PMID: 33575431 Free PMC article. Review.
-
Generation of gene-corrected functional osteoclasts from osteopetrotic induced pluripotent stem cells.Stem Cell Res Ther. 2020 May 15;11(1):179. doi: 10.1186/s13287-020-01701-y. Stem Cell Res Ther. 2020. PMID: 32414402 Free PMC article.
-
Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells.Nat Commun. 2022 May 19;13(1):2810. doi: 10.1038/s41467-022-30558-3. Nat Commun. 2022. PMID: 35589724 Free PMC article.
-
Metabolic bone disorders and the promise of marine osteoactive compounds.Cell Mol Life Sci. 2023 Dec 20;81(1):11. doi: 10.1007/s00018-023-05033-x. Cell Mol Life Sci. 2023. PMID: 38117357 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical